Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Rituximab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention. Browse Rituximab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1304
Shown on this page
12
Current sort
Recently updated
Therapy scope
Rituximab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Rituximab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 493–504 of 1,304 matching trials for Rituximab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1Phase 2 Interventional

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

NCT01484093
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Terminated Phase 1 Interventional

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

NCT03121677
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Personalized tumor vaccine, Poly ICLC, Nivolumab, Peripheral blood draws, Leukapheresis, Rituximab, Biopsy
Biological · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Terminated Phase 4 Interventional Results available

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

NCT02749292
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

NCT01267812
View directory record Official record
Conditions
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
bortezomib, rituximab, laboratory biomarker analysis, immunohistochemistry staining method, RNA analysis, gene expression analysis, DNA analysis, pharmacological study, pharmacogenomic studies, Questionnaire Administration
Drug · Biological · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT01399372
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
Interventions
Rituximab, Cytarabine, Methotrexate, Procarbazine, Vincristine, low-dose whole-brain radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

NCT05508009
View directory record Official record
Conditions
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Drug · Radiation · Device + 1 more
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Interventions
Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Months to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
68
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
104
States / cities
Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Terminated Phase 1 Interventional

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

NCT04156828
View directory record Official record
Conditions
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Copanlisib, Gemcitabine, Carboplatin, Dexamethasone, Rituximab, Pegfilgrastim
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

NCT00060346
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
153
States / cities
Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

NCT00074282
View directory record Official record
Conditions
Leukemia
Interventions
rituximab, cyclophosphamide, pentostatin, Alemtuzumab
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
143
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 11:10 AM EDT

About this Rituximab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Rituximab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Rituximab.